Skip to content
DataLookout
Menu

NCT07896005

A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Progression-free survival (PFS) based on blinded independent central review (BICR)
Timeframe: From randomization until disease progression or death from any cause, whichever occurs first, up to approximately 40 months.

Secondary (6)

Overall Survival (OS)
Progression-Free Survival (PFS) assessed by the Investigator
Objective Response Rate (ORR) assessed by the Investigator and BICR
Duration of Response (DoR) assessed by the Investigator and BICR
Disease Control Rate (DCR) assessed by the Investigator and BICR
Show 1 moreShow less
Incidence and Severity of Adverse Events (AEs), graded according to NCI-CTCAE v6.0

Arms and interventions

SHR-A1811 + Adebrelimab GroupExperimental

SHR-A1811, Adebrelimab Group.

Standard of Care (Tislelizumab + Pemetrexed + Carboplatin/Cisplatin)Active comparator

Tislelizumab, Pemetrexed, Carboplatin/Cisplatin.

Drugs: SHR-A1811 Injection, Adebrelimab Injection, Tislelizumab Injection, Pemetrexed Disodium For Injection, Carboplatin injection, Cisplatin injection

Sites

2 sites in 1 country